PRGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PRGO is not a good buy right now for an impatient investor. The tape is decisively bearish (downtrend + weakening momentum), and the most recent quarter shows deteriorating profitability. While insider buying and bullish-leaning options positioning are constructive, they are not strong enough today to outweigh the negative trend and weak near-term fundamentals. I would avoid buying now and only reconsider after the stock reclaims key resistance (around 14.52–15.20) or after clearer business stabilization.
Trend/momentum are bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend. MACD histogram is -0.133 and expanding negatively, indicating downside momentum is still building rather than bottoming. Price (~13.83) is sitting just below/around S1 (13.836) with the next support at S2 (13.412); a break below 13.41 would open further downside. Near-term resistance is the pivot at 14.521, then R1 at 15.207. Pattern-based stats provided also skew negative (estimated -6.63% next month), aligning with the bearish technical setup.
Intellectia Proprietary Trading Signals
Insiders are buying (buying amount up ~107% over the last month), which is a tangible vote of confidence. Options skew is bullish (low put/call), suggesting sentiment is not panicked. Shares trade well below recent sell-side targets ($18–$20), leaving theoretical upside if execution stabilizes.
No near-term news catalysts in the past week. Technicals are firmly bearish (bearish MA stack; MACD weakening), increasing the odds that support levels fail. Recent sell-side actions skew cautious: JPMorgan downgraded to Neutral and cut targets, highlighting uncertainty in infant formula recovery and OTC trends. The provided pattern-probability outlook also points to continued downside over 1 week/1 month.
Latest reported quarter: 2025/Q3. Revenue fell to $1.043B (-4.06% YoY). Profitability deteriorated sharply: Net income $7.5M (down ~135.71% YoY), EPS $0.05 (down ~133.33% YoY). Gross margin slipped to 36.14% (-2.82% YoY). Overall, this is a weakening growth/profitability trend, which typically makes it harder for a stock to bottom sustainably without a clear operational inflection.
Recent trend: price targets were cut meaningfully and ratings became more cautious. JPMorgan downgraded PRGO to Neutral (from Overweight) and lowered targets (from $32 to $20, later to $18), citing uncertainty in near-term business dynamics. Canaccord kept a Buy but slashed its target from $40 to $20 despite noting a Q3 beat, flagging weak sales trends. Wall Street pro view: upside exists if OTC and infant formula trends stabilize (targets still above the current price), but the dominant concern is visibility—near-term demand/competitive pressure and slower recovery are keeping analysts cautious.
